The Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patients.

There is no fulltext present in this item.

Title:	The Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patients.
Author(s):	Warmenhoven, F.C. ; Rijswijk, H.C.A.M. van ; Engels, Y.M. ; Kan, C.C. ; Prins, J.B. ; Weel, C. van ; Vissers, K.
Publication year:	2012
Source:	Supportive Care in Cancer, vol. 20, iss. 2, (2012), pp. 319-324
ISSN:	0941-4355
DOI:	https://doi.org/10.1007/s00520-010-1082-8
Annotation:	1 februari 2012
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/109712
Display more details
Subject:	NCEBP 7: Effective primary care and public health NCEBP 7: Effective primary care and public health ONCOL 2: Age-related aspects of cancer NCEBP 8: Psychological determinants of chronic illness ONCOL 4: Quality of Care NCEBP 9: Mental health DCN MP - Plasticity and memory NCEBP 7: Effective primary care and public health
Organization:	Primary and Community Care Anesthesiology Psychiatry Medical Psychology
Journal title:	Supportive Care in Cancer
Volume:	vol. 20
Issue:	iss. 2
Page start:	p. 319
Page end:	p. 324
Abstract:	PURPOSE: Depression is highly prevalent in advanced cancer patients, but the diagnosis of depressive disorder in patients with advanced cancer is difficult. Screening instruments could facilitate diagnosing depressive disorder in patients with advanced cancer. The aim of this study was to determine the validity of the Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in advanced cancer patients. METHODS: Patients with advanced metastatic disease, visiting the outpatient palliative care department, were asked to fill out a self-questionnaire containing the Beck Depression Inventory (BDI-II) and a single screening question "Are you feeling depressed?" The mood section of the PRIME-MD was used as a gold standard. RESULTS: Sixty-one patients with advanced metastatic disease were eligible to be included in the study. Complete data were obtained from 46 patients. The area under the curve of the receiver operating characteristics analysis of the BDI-II was 0.82. The optimal cut-off point of the BDI-II was 16 with a sensitivity of 90% and a specificity of 69%. The single screening question showed a sensitivity of 50% and a specificity of 94%. CONCLUSIONS: The BDI-II seems an adequate screening tool for a depressive disorder in advanced cancer patients. The sensitivity of a single screening question is poor.